Learn About MASH Liver Disease and Health

Understanding MASH: What It Is and How It Develops

MASH stands for Metabolic Dysfunction-Associated Fatty Liver Disease. This is a condition where fat builds up in the liver cells, and it's connected to metabolic problems in the body. MASH was previously called NAFLD (Non-Alcoholic Fatty Liver Disease), but doctors changed the name in 2023 to better reflect how the disease develops and progresses.

Get Your Free Sourdough Bread Health Benefits Guide →

The liver is your body's largest internal organ, and it does many important jobs. It filters your blood, makes bile to help digest food, stores nutrients, and removes toxins. When fat makes up more than 5% of the liver's weight, the condition is called fatty liver disease. In MASH, this fat buildup happens alongside metabolic dysfunction—meaning the body isn't processing energy, glucose, and fats the way it should.

MASH develops through stages. The earliest stage is simple steatosis, where fat accumulates but doesn't cause inflammation or damage. Some people stay in this stage for years without problems. However, in other people, the condition progresses to MASH with inflammation and cell damage. This stage is called steatohepatitis. If left unchecked, it can lead to fibrosis (scarring of liver tissue), cirrhosis (severe scarring that damages liver function), and liver failure.

The exact reasons why some people develop MASH are still being studied, but researchers have identified several risk factors. These include obesity, type 2 diabetes, insulin resistance, high blood pressure, and abnormal cholesterol levels. A person doesn't need to have all these conditions—even one or two can increase risk. About 25% of people worldwide have fatty liver disease, making it one of the most common liver conditions today.

Practical Takeaway: Understanding that MASH develops gradually and has different stages helps explain why early detection matters. Knowing the metabolic factors involved—insulin resistance, obesity, and metabolic syndrome—can guide conversations with healthcare providers about screening and prevention.

Who Is at Risk for MASH and Why

Certain groups of people face higher risk for developing MASH. Age plays a role—the condition is more common in middle-aged and older adults, though it increasingly appears in younger people and even children. Men are diagnosed more often than women, though women's risk increases significantly after menopause.

Learn About New Arthritis Therapies and Joint Health →

The strongest risk factor for MASH is obesity. Studies show that about 80% of people with obesity have some form of fatty liver disease. However, it's important to note that thin people can also develop MASH—a condition called "lean MASH." This occurs in roughly 5-10% of MASH cases and is sometimes harder to detect because people don't expect liver problems in someone at normal weight.

Type 2 diabetes significantly increases MASH risk. About 50-70% of people with type 2 diabetes have MASH. Insulin resistance—when cells don't respond properly to insulin—is a key mechanism. The pancreas compensates by making more insulin, which can promote fat storage in the liver and trigger inflammation. People with metabolic syndrome (a cluster of conditions including high blood pressure, high blood sugar, excess body fat, and abnormal cholesterol) have substantially higher MASH risk.

Other risk factors include:

• High triglycerides or abnormal cholesterol levels
• Polycystic ovary syndrome (PCOS) in women
• Sleep apnea, which disrupts breathing during sleep
• Certain genetic variations that affect liver fat metabolism
• Ethnicity—Hispanic and Asian populations show higher prevalence in some studies
• Sedentary lifestyle and lack of physical activity
• Diet high in refined carbohydrates and added sugars

Environmental and lifestyle factors matter significantly. Consuming high amounts of fructose (found in sugary drinks and processed foods) is linked to liver fat accumulation. Regular alcohol use, even moderate amounts, can worsen liver disease, though MASH itself develops without significant alcohol consumption.

Practical Takeaway: If you have obesity, type 2 diabetes, metabolic syndrome, or multiple risk factors, discussing liver health screening with a doctor becomes more important. Risk assessment helps guide decisions about lifestyle changes and monitoring.

Recognizing Symptoms and Why Early Detection Matters

One challenging aspect of MASH is that many people with early-stage disease have no symptoms at all. The liver doesn't have pain receptors, so fatty liver disease often progresses silently. A person might have MASH for years without knowing it. This is why MASH is sometimes called a "silent" disease.

Learn About the Commodity Supplemental Food Program →

When symptoms do appear, they typically develop as the disease progresses. Early warning signs may include fatigue, weakness, or general tiredness that seems out of proportion to activity level. Some people report a dull pain or fullness on the right side of the upper abdomen, where the liver is located. Others notice abdominal swelling or bloating.

As MASH advances, additional symptoms can emerge:

• Loss of appetite
• Nausea or vomiting
• Jaundice (yellowing of skin and eyes)
• Dark urine or pale stools
• Easy bruising or bleeding
• Swelling in the legs and ankles (edema)
• Confusion or difficulty concentrating
• Fluid accumulation in the abdomen (ascites)

These advanced symptoms indicate that liver function is significantly impaired and medical attention is urgent. However, waiting for symptoms before seeking care means the disease may have already progressed substantially.

Early detection during the fatty liver stage—before significant scarring develops—is crucial because the liver has remarkable healing ability. If MASH is caught before cirrhosis develops, lifestyle changes and medical management can halt or slow disease progression. Once cirrhosis occurs, the damage is largely permanent. Research shows that people who lose 5-10% of body weight can reduce liver fat by roughly 30%, and weight loss of 10% or more can reduce inflammation and improve fibrosis markers.

Healthcare providers may discover MASH incidentally during imaging tests done for other reasons, or through routine blood tests showing elevated liver enzymes. This accidental discovery is common because the disease doesn't announce itself.

Practical Takeaway: Because MASH often causes no symptoms in early stages, people with risk factors shouldn't wait for symptoms before discussing screening options with their healthcare provider. Blood tests and imaging can detect the condition before symptoms develop, when treatment options are most effective.

How Doctors Diagnose and Assess MASH

Diagnosing MASH typically involves several steps because no single test definitively proves the disease. Doctors usually start by looking at liver enzymes and function through blood work. Common blood tests measure ALT (alanine aminotransferase) and AST (aspartate aminotransferase), which are enzymes released when liver cells are damaged. Elevated levels suggest liver stress, though they don't indicate the specific cause.

Get Your Free Device Battery Health Guide →

Blood tests also check platelet count, bilirubin levels, and albumin. A decreased platelet count, in particular, can signal that fibrosis (scarring) has developed, since scar tissue interferes with normal blood flow through the liver. Doctors may calculate the AST-to-platelet ratio, or APRI score, to estimate the likelihood of significant fibrosis.

Imaging tests play an important role in diagnosis. Ultrasound is often the first imaging test because it's non-invasive, doesn't use radiation, and is relatively inexpensive. It can show fatty infiltration of the liver, though it becomes less reliable at detecting fat once more than 30% of the liver is affected. CT (computed tomography) and MRI (magnetic resonance imaging) scans provide more detailed images and can measure liver fat content more precisely. A newer technique called MR elastography uses magnetic resonance imaging to assess liver stiffness, which indicates the degree of fibrosis.

Specialized blood tests have emerged to assess fibrosis without biopsy.